Recently, a systemic hypoxia-inducible factor−HIF-2α inhibitor was approved by the Food and Drug Administration−FDA for adult patients with VHL-ccRCC not requiring immediate surgery [6–8]. Here, VHL is linked to nonpapillary renal cell carcinoma.